ERBB2 and breast carcinoma: In a previous section, we discussed the involvement of EVs in the escape to immunotherapies, by acting as a sink for immuno-targeting drugs specific for cancer-associated antigens such as CD20 in the case of B cell lymphoma [85], HER2 in the case of breast cancer [86] and more generally, PD-L1 [87, 88].